Esperion Therapeutics, Inc.
$1.7M 27,251 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
bioMerieux Inc
bioMerieux Inc reported $1,715,467.98 across General Payments, Research, and Ownership to 600 physicians and teaching hospitals across 771 transactions.
- $1.7M
- All-tracks total
- 771
- Transactions
- 600
- Recipients
- +$343.3K
- General Payments vs PY2023
bioMerieux Inc reported $1,715,467.98 across all CMS Open Payments tracks (General + Research + Ownership) to 600 physicians and teaching hospitals in Program Year 2024 - ranking #488 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $716,765.40, averaging $2.9K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer biomerieux-inc bioMerieux Inc
$1.7M · #488/1,925 · 0.0% industry · PY2024
- TOT $1.7M
- RANK #488
- SHARE 0.0%
- TXN 771
- RCP 600
- CAT 5
- GEN $716.8K
- ΔGEN +$343.3K
- TOP1 23.7%
- PY 2024
Volume peers
Nearest volume peer: Esperion Therapeutics, Inc. ($1.7M)
bioMerieux Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
bioMerieux Inc's CMS-reported General Payments increased by $343.3K (+91.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BIOMERIEUX INCPY2023: BIOMERIEUX INCPY2024: bioMerieux Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $373,459.99
- PY2024
- $716,765.40
What the Data Shows for bioMerieux Inc
Rank #488 of 1,925 companies in CMS Open Payments for 2024 belongs to bioMerieux Inc, which reported $1,715,467.98 across 771 transactions to 600 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $2.2K per transaction and $2.9K per recipient.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Debt Forgiveness" at $467.2K, accounting for 65.2% of this company's General Payments and 9 transactions.
General Payment Breakdown by Type
bioMerieux Inc made 5 types of general payments. "Debt Forgiveness" is the largest category at $467.2K, 65.2% of General Payments.
bioMerieux Inc reports 5 general-payment categories - the top three are Debt Forgiveness (65.2%), Travel and Lodging (14.1%), and Compensation for Services Other Than Consulting (9.2%). The remaining 2 categories make up 11.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How bioMerieux Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Debt Forgiveness | $467.2K | 9 | 65.2% |
| Travel and Lodging | $101.3K | 72 | 14.1% |
| Compensation for Services Other Than Consulting | $65.8K | 25 | 9.2% |
| Consulting Fee | $58.9K | 15 | 8.2% |
| Food and Beverage | $23.5K | 479 | 3.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $487,934.37 (68.1%) of $716,765.40 in this company's General Payments records across 386 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for bioMerieux Inc
The five named recipients with the highest reported General Payments from this company
- 1
Beth Israel Deaconess Medical Center
$169,820.23 across 1 reported transactions
- 2
Community First Medical Center
$132,002.37 across 1 reported transactions
- 3
Georgetown Memorial Hospital
$96,385.78 across 1 reported transactions
- 4
St. Alexius Hospital
$63,528.65 across 1 reported transactions
- 5
Denver Niles
$26,197.34 across 18 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as bioMerieux Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about bioMerieux Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with bioMerieux Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Pharmacosmos Therapeutics Inc.
$1.7M 7,020 recipients
Compare payment profiles
Y-mAbs Therapeutics, Inc.
$1.7M 159 recipients
Compare payment profiles
Shionogi Inc
$1.7M 5,823 recipients
Compare payment profiles
Dompe US, Inc.
$1.7M 11,308 recipients
Compare payment profiles
Patterson Companies, Inc.
$1.7M 7,273 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.